Notes
obinutuzumab + chlorambucil
Reference
Soini E, et al. Cost-Effectiveness of First-Line Chronic Lymphocytic Leukemia Treatments When Full-Dose Fludarabine Is Unsuitable. Clinical Therapeutics : 9 Mar 2016. Available from: URL: http://doi.org/10.1016/j.clinthera.2016.02.005
Rights and permissions
About this article
Cite this article
Obinutuzumab best value for CLL if fludarabine unsuitable. PharmacoEcon Outcomes News 749, 24 (2016). https://doi.org/10.1007/s40274-016-2911-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2911-x